Wire open Last filed Lilly Pennsylvania plant breaks ground with capacity built for unapproved retatrutide RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
RoutineEXPExplainer

Oral peptide delivery formulator sets out three ways past poor bioavailability

An Alcami formulation scientist told PharmTech how coatings, self emulsifying systems and solid dispersions can help peptides survive the gut, and why the SNAC benchmark behind oral semaglutide brings large tablets and strict intake rules.

Editorial illustration for the story: Oral peptide delivery formulator sets out three ways past poor bioavailability
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

An Alcami formulation scientist told PharmTech that polymethacrylate coatings, self emulsifying systems and solid dispersions can raise the oral bioavailability of peptides, and set them against the SNAC enhancer.

Why it matters

Most peptide drugs are still injected because the gut breaks them down. SNAC works in oral semaglutide but needs large tablets and strict intake rules.

What's next

Developers are testing these formulation tools alongside structural changes to the molecules; no new trial data were reported in the interview.

Oral peptide delivery remains one of the hardest problems in drug formulation, and a new PharmTech video interview sets out the tools developers use to work around it. Robert Sciscento, a senior formulation scientist at contract manufacturer Alcami, named three formulation routes and weighed them against SNAC, the absorption enhancer behind oral semaglutide tablets. The interview, published on 17 November, offers no new trial data. It is a practitioner's view of why most peptide drugs are still injected.

Why peptides struggle as pills

Peptides are chains of amino acids, and the gut handles them much like food. Stomach acid and digestive enzymes break them apart, and the intact molecules that survive are usually too large and too polar to cross the gut wall with ease. A PharmTech feature by Cynthia A. Challener, published on 2 November, put the oral bioavailability of peptides as low as 1% to 2%, meaning only a tiny share of a swallowed amount reaches the blood. Most peptides fall into class III or IV of the Biopharmaceutical Classification System, the groups defined by poor permeability. That is why insulin, semaglutide and tirzepatide reached patients first as injections, and why oral peptide delivery needs a change to the molecule, a change to the tablet, or both.

Challener's feature covered the molecule side: cyclization, lipidation, PEGylation, swapping in D amino acids and other structural edits that make a peptide harder to digest. William Fang of WuXi TIDES told the magazine that peptide bioavailability by mouth stays modest even when molecule and formulation are tuned together. The new interview covers the formulation side, the excipients and processes that shield a peptide on its way through the gut. The interest is commercial as well as scientific. Oral GLP 1 medicines are now on the market, including the first GLP 1 pill cleared for weight management, and developers are working on tablets for other peptide targets. Sciscento spoke in general terms and did not report results from any named client program.

Coatings and self emulsifying systems

The first tool Sciscento described is a polymethacrylate coating, sold under names such as Acryl EZE and EUDRAGIT. These enteric coatings stay intact in the acidic stomach and dissolve at a chosen pH further along the gastrointestinal tract, so the drug is released where it has a better chance of being absorbed. For a peptide, he told PharmTech, that targeted release can separate a formulation with no measurable bioavailability from one with a meaningful gain. Coatings are an established technology in oral solid dose work, which lowers the technical risk for a developer. On their own, however, they address exposure to stomach acid rather than the barrier of the gut wall, so they are often only one layer of a larger design.

For a peptide, he told PharmTech, that targeted release can separate a formulation with no measurable bioavailability from one with a meaningful gain.

The second tool is a self emulsifying drug delivery system, known as SEDDS. Here the peptide sits in a blend of oil, surfactant and cosolvent that forms a fine emulsion when it meets gut fluid, which can raise absorption. Sciscento noted that many formulators already know the format from softgel capsules and from poorly soluble small molecules in classes II and IV. To turn the liquid into a solid dose, the blend holding the dissolved drug is loaded onto a highly porous carrier such as microcrystalline cellulose. The loaded powder can then be pressed into tablets or filled into capsules. Sciscento did not cite bioavailability figures for any marketed peptide product built on SEDDS during the interview, so the size of the gain remains case by case.

Solid dispersions and the SNAC benchmark

The third and most complex route is a solid dispersion. The peptide is held inside a polymer matrix that guards it against breakdown in the stomach and along the rest of the gut. The choice of polymer can raise both solubility and stability, Sciscento said, and he named Soluplus, an amphiphilic graft copolymer, as one option that does both. Then there is SNAC, a permeation enhancer, meaning a compound that helps a molecule pass through the gut lining. It is best known from Rybelsus, the oral semaglutide tablet, and Sciscento called it an industry proven benchmark. The table sets out the four approaches he discussed, what each one is meant to do and the example he named for it.

ApproachWhat it is meant to doExample named
Polymethacrylate coatingShields the drug from acid and releases it at a set pHAcryl EZE, EUDRAGIT
Self emulsifying systemOil, surfactant and cosolvent blend that emulsifies in gut fluidBlend loaded on microcrystalline cellulose
Solid dispersionHolds the peptide in a protective polymer matrixSoluplus
Permeation enhancerHelps the peptide cross the gut liningSNAC in Rybelsus

The benchmark has costs. SNAC usually has to be used in large amounts, and in the example Sciscento gave, the enhancer outweighs the peptide by roughly a hundred times or more. The result is a large tablet, which he said can make patients less likely to take it as prescribed. Tablets built on SNAC also come with strict intake rules: they must be swallowed on an empty stomach with very little water, and they may work less well when patients do not follow those rules. Small molecule GLP 1 pills, such as the non peptide pill covered here earlier, avoid the peptide absorption problem by design, though they are different drugs with their own trial records and side effect profiles.

Moisture and scale up limits

In a companion PharmTech video on scaling up oral peptides, Sciscento turned from absorption to the factory floor. An oral peptide dose is usually larger than an injected one, he said, so each batch of tablets needs much more active ingredient than an injectable product. Many peptides also break down in the presence of moisture. That generally rules out wet granulation and steers developers toward direct blending or dry granulation methods such as roller compaction. Manufacturers can add protection at several stages: humidity control during processing, a moisture barrier coat on the tablet and packaging that keeps water out. Each of those layers adds process steps that a manufacturer has to control and document before a product can reach patients.

None of these tools removes the basic limit of oral peptide delivery. Even a well designed tablet passes only a small fraction of its peptide into the blood, which is why oral products need far more drug substance than injections of the same medicine. That adds demand on peptide ingredient plants at a time when large makers are already expanding capacity. Some developers are moving in the opposite direction, toward longer acting injections that cut the number of shots, such as the AdoXLong platform tested in pigs. For patients, the practical point is simple. An oral peptide is not a stronger or weaker version of an injection by default, and how well it works depends on its formulation and on following its label.

Conclusion

Oral peptide delivery still depends on protecting a fragile molecule and helping it across the gut wall. Sciscento's interview lists the main formulation tools, from enteric coatings and self emulsifying systems to solid dispersions and the SNAC benchmark, but it brings no new data. For now, each oral peptide product trades convenience against tablet size, strict intake rules and the extra drug substance a plant must make.

More from the wire

Same thread first, then the same desk.